In This Article:
-
Total Revenue: $378.1 million for Q3 2024.
-
Proprietary Product Portfolio Growth: 18% year-over-year.
-
Vivitrol Net Sales: $113.7 million, 14% year-over-year growth.
-
Aristada Net Sales: $84.7 million.
-
Lybalvi Net Sales: $74.7 million, 37% year-over-year growth.
-
Manufacturing and Royalty Revenues: $105.1 million.
-
Cost of Goods Sold: $63.1 million.
-
R&D Expenses: $59.9 million.
-
SG&A Expenses: $150.4 million.
-
GAAP Net Income from Continuing Operations: $92.8 million.
-
Non-GAAP Net Income from Continuing Operations: $121.4 million.
-
EBITDA from Continuing Operations: $112.3 million.
-
Cash and Total Investments: $927.8 million.
-
Share Repurchase: $116 million deployed to repurchase 4.4 million shares.
Release Date: October 24, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Alkermes PLC (NASDAQ:ALKS) reported strong growth in its proprietary product portfolio, with net sales reaching $273 million, reflecting an 18% year-over-year increase.
-
Vivitrol net sales grew by 14% year-over-year, driven by demand in the alcohol dependence indication, with expectations to reach the high end of the $410-$430 million range for the full year.
-
Lybalvi showed significant growth with net sales of $74.7 million, a 37% year-over-year increase, supported by strong demand and expanded prescriber reach.
-
The company is in a strong financial position with $927.8 million in cash and investments, and has repurchased 4.4 million shares as part of a $400 million share repurchase program.
-
Alkermes PLC (NASDAQ:ALKS) is advancing its ALKS 2680 clinical program with positive phase 1B data, and phase 2 studies are underway, expected to be a transformative catalyst for the company.
Negative Points
-
The Aristada product family experienced softness in the schizophrenia long-acting antipsychotic market, with expectations for net sales to be at the lower end of the $340-$360 million range.
-
Manufacturing and royalty revenues decreased, with a notable drop in revenues from long-acting Invega products, impacting overall financial performance.
-
The company anticipates a significant impact on royalty and manufacturing revenues in 2025, with a projected decrease of approximately $200 million due to the conclusion of certain royalties and manufacturing transitions.
-
Operating expenses are expected to increase modestly in 2025, driven by investments in the ALKS 2680 program and expansion of the psychiatry commercial footprint.
-
Alkermes PLC (NASDAQ:ALKS) faces competitive dynamics in the antipsychotic space, requiring increased investment in personal promotion to maintain market share.